Early Phase II Trials for Cocaine Medication Development - 1
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders; Substance-Related Disorders
Intervention: Risperidone (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Edward Nunes, M.D., Principal Investigator, Affiliation: Research Foundation for Mental Hygiene
Summary
The purpose of this study is to develop models for early Phase II testing of potential
medications for cocaine dependence: amoxapine, risperidone and other agents.
Clinical Details
Official title: Early Phase II Trials for Cocaine Medication Development
Study design: Treatment
Primary outcome: Side effectsCraving Drug use Retention
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
Research Foundation for Mental Hygiene, New York, New York 10032, United States
Additional Information
Starting date: June 1994
Last updated: June 23, 2005
|
